About Confluence Life Sciences
Confluence Life Sciences is a company based in St. Louis (United States) founded in 2010 was acquired by Aclaris Therapeutics in August 2017.. Confluence Life Sciences has raised $12.23 million across 9 funding rounds from investors including Aclaris Therapeutics, HHS and Mercury Fund. Confluence Life Sciences operates in a competitive market with competitors including Syndax, Annexon, Auron Therapeutics, Clovis Oncology and C4X Discovery, among others.
- Headquarter St. Louis, United States
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$12.23 M (USD)
in 9 rounds
-
Latest Funding Round
$225 K (USD), Grant
Jul 01, 2017
-
Investors
Aclaris Therapeutics
& 7 more
-
Employee Count
Employee Count
-
Acquired by
Aclaris Therapeutics
(Aug 08, 2017)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Confluence Life Sciences
Confluence Life Sciences has successfully raised a total of $12.23M across 9 strategic funding rounds. The most recent funding activity was a Grant round of $225 thousand completed in July 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 9
- Last Round Grant — $225,000
-
First Round
First Round
(18 Oct 2010)
- Investors Count 7
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2017 | Amount | Grant - Confluence Life Sciences | Valuation |
investors |
|
| Apr, 2016 | Amount | Series B - Confluence Life Sciences | Valuation |
investors |
|
| Jul, 2015 | Amount | Series B - Confluence Life Sciences | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Confluence Life Sciences
Confluence Life Sciences has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include Aclaris Therapeutics, HHS and Mercury Fund. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage investments are directed toward US, India, and Canada firms.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
Tech companies focused VC firm operating across Missouri
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Confluence Life Sciences
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Confluence Life Sciences
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Confluence Life Sciences Comparisons
Competitors of Confluence Life Sciences
Confluence Life Sciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Syndax, Annexon, Auron Therapeutics, Clovis Oncology and C4X Discovery, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Targeted therapies for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
|
| domain | founded_year | HQ Location |
Developer of cancer therapeutics for the treatment of blood cancer
|
|
| domain | founded_year | HQ Location |
Develops innovative immunotherapy drugs for cancer treatment.
|
|
| domain | founded_year | HQ Location |
Developer of optimized drug discovery and design services
|
|
| domain | founded_year | HQ Location |
Anti-cancer immunotherapies are developed targeting tumor micro-environment.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Confluence Life Sciences
Frequently Asked Questions about Confluence Life Sciences
When was Confluence Life Sciences founded?
Confluence Life Sciences was founded in 2010.
Where is Confluence Life Sciences located?
Confluence Life Sciences is headquartered in St. Louis, United States. It is registered at St. Louis, Missouri, United States.
Is Confluence Life Sciences a funded company?
Confluence Life Sciences is a funded company, having raised a total of $12.23M across 9 funding rounds to date. The company's 1st funding round was a Series B of $2.4M, raised on Oct 18, 2010.
What does Confluence Life Sciences do?
Confluence Life Sciences (CLS) is a drug discovery and early development company which is focusing on developing kinase inhibitors using its proprietary technology. Its platform KINect claims to accelerate the identification of drug candidates targeting active-site cysteine-containing kinases. The platform has a thiol-directed chemical library of protein kinase inhibitors which has been utilized in multiple drug discovery programs. Its internal development pipeline has programs for cancer immunotherapy and autoimmune diseases (IL-2 Inducible T-Cell Kinase (ITK) Tyrosine-protein Kinase inhibitors). It is also developing programs for inflammation and cancer externally in partnership with other pharmacy companies.
Who are the top competitors of Confluence Life Sciences?
Confluence Life Sciences's top competitors include Syndax, iTeos Therapeutics and Annexon.
Who are Confluence Life Sciences's investors?
Confluence Life Sciences has 8 investors. Key investors include Aclaris Therapeutics, HHS, Mercury Fund, Epidarex Capital, and Missouri Technology.